Adeno-associated viruses (AAVs) are solidifying their role as a cornerstone of gene therapy, driven by innovations in vector design and manufacturing practices. A recent three-part webinar series hosted by the United States Pharmacopeia (USP) delves into the current AAV landscape, offering insights into capsid characterization and the critical role of plasmid DNA as a starting material. This series aims to equip pharma professionals with the knowledge necessary to navigate the complexities of AAV development.
Experts from USP and the industry will present real-world case studies and practical strategies to tackle common challenges in AAV analytics and material controls. By addressing issues such as capsid characterization and the interplay between production and analytical teams, the series emphasizes the importance of collaboration in optimizing AAV manufacturing. This initiative not only enhances understanding but also fosters a proactive approach to overcoming hurdles in gene therapy development.
Start your 7-day trial and see what the database can do →
